← Russell 3000 cross-section

IDXX IDEXX LABORATORIES INC /DE

Trailing twelve months to 2026-06-30 · as filed 2026-08-04, not restated
Healthcare

Scale

Market cap
$43.4bn
Revenue TTM
$4.6bn
Net income TTM
$1.1bn
Free cash flow
$1.3bn
Composite score
57.7
Sector rank
#266

Valuation

P / E
38.1
EV / EBITDA
27.0
EV / sales
9.6
FCF yield
2.89%
Earnings yield vs 10-yr
-2.10pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
25.0%
EBITDA margin
35.4%
ROE
70.7%
ROIC
85.0%
Revenue growth
12.8%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Management believes that reporting organic revenue growth provides useful information to investors by facilitating easier comparisons of our revenue performance with prior and future periods and to the performance of our peers. We exclude from organic revenue growth the effect of changes in foreign currency exchange rates because changes in foreign currency exchange rates are not under management’s control, are subject to volatility, and can obscure underlying business trends. …IDEXX LABORATORIES INC /DE, 10-Q, period ended 2026-06-30, filed 2026-08-04

Read the full passage →